These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30717707)

  • 1. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
    Strauss VY; Shaw R; Virdee PS; Hurt CN; Ward E; Tranter B; Patel N; Bridgewater J; Parsons P; Radhakrishna G; O'Neill E; Sebag-Montefiore D; Hawkins M; Corrie PG; Maughan T; Mukherjee S
    BMC Cancer; 2019 Feb; 19(1):121. PubMed ID: 30717707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
    Mukherjee S; Qi C; Shaw R; Jones CM; Bridgewater JA; Radhakrishna G; Patel N; Holmes J; Virdee PS; Tranter B; Parsons P; Falk S; Wasan HS; Ajithkumar TV; Holyoake D; Roy R; Scott-Brown M; Hurt CN; O'Neill E; Sebag-Montefiore D; Maughan TS; Hawkins MA; Corrie P
    Eur J Cancer; 2024 Sep; 209():114236. PubMed ID: 39059185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
    Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S
    Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
    Hurt CN; Mukherjee S; Bridgewater J; Falk S; Crosby T; McDonald A; Joseph G; Staffurth J; Abrams RA; Blazeby JM; Bridges S; Dutton P; Griffiths G; Maughan T; Johnson C
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):810-8. PubMed ID: 26530749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
    Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
    Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
    Holyoake DLP; Warren DR; Hurt C; Aznar M; Partridge M; Mukherjee S; Hawkins MA
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):418-426. PubMed ID: 29602584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
    Faisal F; Tsai HL; Blackford A; Olino K; Xia C; De Jesus-Acosta A; Le DT; Cosgrove D; Azad N; Rasheed Z; Diaz LA; Donehower R; Laheru D; Hruban RH; Fishman EK; Edil BH; Schulick R; Wolfgang C; Herman J; Zheng L
    Am J Clin Oncol; 2016 Feb; 39(1):18-26. PubMed ID: 24351782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
    Koay EJ; Zaid M; Aliru M; Bagereka P; Van Wieren A; Rodriguez MJ; Jacobson G; Wolff RA; Overman M; Varadhachary G; Pant S; Wang H; Tzeng CW; Ikoma N; Kim M; Lee JE; Katz MH; Tamm E; Bhosale P; Taniguchi CM; Holliday EB; Smith GL; Ludmir EB; Minsky BD; Crane CH; Koong AC; Das P; Wang X; Javle M; Krishnan S
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):444-453. PubMed ID: 35863672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
    Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
    Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
    Hudson E; Hurt C; Mort D; Brewster AE; Iqbal N; Joseph G; Crosby TD; Mukherjee S
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):27-35. PubMed ID: 19896352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
    Ioka T; Furuse J; Fukutomi A; Mizusawa J; Nakamura S; Hiraoka N; Ito Y; Katayama H; Ueno M; Ikeda M; Sugimori K; Okano N; Shimizu K; Yanagimoto H; Okusaka T; Ozaka M; Todaka A; Nakamori S; Tobimatsu K; Sata N; Kawashima Y; Hosokawa A; Yamaguchi T; Miyakawa H; Hara H; Mizuno N; Ishii H;
    Jpn J Clin Oncol; 2021 Feb; 51(2):235-243. PubMed ID: 33164066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.
    Mukherjee S; Hurt CN; Gwynne S; Sebag-Montefiore D; Radhakrishna G; Gollins S; Hawkins M; Grabsch HI; Jones G; Falk S; Sharma R; Bateman A; Roy R; Ray R; Canham J; Griffiths G; Maughan T; Crosby T
    Eur J Cancer; 2017 Mar; 74():38-46. PubMed ID: 28335886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.